For ACS patients with significantly elevated TyG, prolonging the course of intensive antithrombotic therapy or early initiation of GLP-1 receptor agonists (which possess both anti-inflammatory and metabolic regulatory properties) may reduce the risk of short-term recurrent ischemia. The gene discussed is GLP1R; the disease is ischemia.